with chronic or relapsing idiopathic thrombotic thrombocytopenic purpura? Transplant Proc 2002.

34(7):2953–2954.

69. Rice HE, Oldham KT, Hillery CA, et al. Clinical and hematologic benefits of partial splenectomy for

congenital hemolytic anemias in children. Ann Surg 2003;237(2):281–288.

70. Balint GP, Balint PV. Felty’s syndrome. Best Pract Res Clin Rheumatol 2004; 18(5):631–645.

71. van Krieken JH, Breedveld FC, de Velde J. The spleen in Felty’s syndrome: a histological,

morphometrical, and immunohistochemical study. Eur J Haematol 1988;40(1):58–64.

72. Blumfelder TM, Logue GL, Shimm DS. Felty’s syndrome: effects of splenectomy upon granulocyte

count and granulocyte-associated IgG. Ann Intern Med 1981;94(5):623–628.

73. Logue GL, Huang AT, Shimm DS. Failure of splenectomy in Felty’s syndrome. The role of antibodies

supporting granulocyte lysis by lymphocytes. N Engl J Med 1981;304(10):580–583.

74. Perrotta S, Gallagher PG, Mohandas N. Hereditary spherocytosis. Lancet 2008;372(9647):1411–

1426.

75. Eber S, Lux SE. Hereditary spherocytosis—defects in proteins that connect the membrane skeleton

to the lipid bilayer. Semin Hematol 2004; 41(2):118–141.

76. Bolton-Maggs PH, Stevens RF, Dodd NJ, et al. Guidelines for the diagnosis and management of

hereditary spherocytosis. Br J Haematol 2004;126(4):455–474.

77. Reliene R, Mariani M, Zanella A, et al. Splenectomy prolongs in vivo survival of erythrocytes

differently in spectrin/ankyrin- and band 3-deficient hereditary spherocytosis. Blood

2002;100(6):2208–2215.

78. Tsereteli Z, Smith CD, Branum GD, et al. Are the favorable outcomes of splenectomy predictable

inpatients with idiopathic thrombocytopenic purpura (ITP)? Surg Endosc 2001;15(12):1386–1389.

79. Olivieri NF, Nathan DG, MacMillan JH, et al. Survival in medically treated patients with

homozygous beta-thalassemia. N Engl J Med 1994; 331(9):574–578.

80. Pinca A, Di Palma A, Soriani S, et al. Effectiveness of partial splenic embolization as treatment for

hypersplenism in thalassaemia major: a 7-year follow up. Eur J Haematol, 1992;49(2):49–52.

81. Idowu O, Hayes-Jordan A. Partial splenectomy in children under 4 years of age with

hemoglobinopathy. J Pediatr Surg 1998;33(8):1251–1253.

82. al-Salem AH, al-Dabbous I, Bhamidibati P. The role of partial splenectomy in children with

thalassemia. Eur J Pediatr Surg 1998;8(6):334–338.

83. Levasseur DN, Ryan TM, Reilly MP, et al. A recombinant human hemoglobin with anti-sickling

properties greater than fetal hemoglobin. J Biol Chem 2004;279(26):27518–27524.

84. Corash L, Shafer B, Blaese RM. Platelet-associated immunoglobulin, platelet size, and the effect of

splenectomy in the Wiskott-Aldrich syndrome. Blood 1985;65(6):1439–1443.

85. Mullen CA, Anderson KD, Blaese RM. Splenectomy and/or bone marrow transplantation in the

management of the Wiskott-Aldrich syndrome: long-term follow-up of 62 cases. Blood

1993;82(10):2961–2966.

86. Vermi W, Blanzuoli L, Kraus MD, et al., The spleen in the Wiskott-Aldrich syndrome:

Histopathologic abnormalities of the white pulp correlate with the clinical phenotype of the

disease. Am J Surg Pathol 1999;23(2):182–191.

87. Elliott MA, Tefferi A. Splenic irradiation in myelofibrosis with myeloid metaplasia: A review. Blood

Rev 1999;13(3):163–170.

88. Delpero JR, Houvenaeghel G, Gastaut JA, et al. Splenectomy for hypersplenism in chronic

lymphocytic leukaemia and malignant non-Hodgkin’s lymphoma. Br J Surg 1990;77(4):443–449.

89. Thiruvengadam R, Piedmonte M, Barcos M, et al. Splenectomy in advanced chronic lymphocytic

leukemia. Leukemia 1990;4(11):758–760.

90. Neal TF Jr, Tefferi A, Witzig TE, et al. Splenectomy in advanced chronic lymphocytic leukemia: A

single institution experience with 50 patients. Am J Med 1992. 93(4):435–440.

91. Seymour JF, Cusack JD, Lerner SA, et al. Case/control study of the role of splenectomy in chronic

lymphocytic leukemia. J Clin Oncol 1997; 15(1):52–60.

92. Savage DG, Szydlo RM, Goldman JM. Clinical features at diagnosis in 430 patients with chronic

myeloid leukaemia seen at a referral centre over a 16-year period. Br J Haematol 1997;96(1):111–

116.

2024

93. Hester JP, Waddell CC, Coltman CA Jr, et al. Response of chronic myelogenous leukemia patients

to COAP-splenectomy. A Southwest Oncology Group study. Cancer 1984;54(9):1977–1982.

94. The Italian Cooperative Study Group on Chronic Myeloid Leukemia. Results of a prospective

randomized trial of early splenectomy in chronic myeloid leukemia. Cancer 1984;54(2):333–338.

95. Bouvet M, Babiera GV, Termuhlen PM, et al. Splenectomy in the accelerated or blastic phase of

chronic myelogenous leukemia: A single-institution, 25-year experience. Surgery 1997;122(1):20–

25.

96. Morel P, Dupriez B, Gosselin B, et al. Role of early splenectomy in malignant lymphomas with

prominent splenic involvement (primary lymphomas of the spleen). A study of 59 cases. Cancer

1993;71(1):207–215.

97. Nair S, Shukla J, Chandy M. Non-Hodgkin’s lymphoma presenting with prominent splenomegaly—

clinicopathologic diversity in relationship to immunophenotype. Acta Oncol 1997;36(7):725–727.

98. Lehne, G, Hannisdal E, Langholm R, et al. A 10-year experience with splenectomy in patients with

malignant non-Hodgkin’s lymphoma at the Norwegian Radium Hospital. Cancer 1994;74(3):933–

939.

99. Tsimberidou AM, Catovsky D, Schlette E, et al. Outcomes in patients with splenic marginal zone

lymphoma and marginal zone lymphoma treated with rituximab with or without chemotherapy or

chemotherapy alone. Cancer 2006;107(1):125–135.

100. Brodsky J, Abcar A, Styler M. Splenectomy for non-Hodgkin’s lymphoma. Am J Clin Oncol.

1996;19(6):558–561.

101. Grever MR. How I treat hairy cell leukemia. Blood 2010;115(1):21–28.

102. Tallman MS, Hakimian D, Peterson L. Massive splenomegaly in hairy cell leukemia. J Clin Oncol

1998;16(3):1232–1233.

103. Katz SC, Pachter HL. Indications for splenectomy. Am Surg 2006;72(7): 565–580.

104. Smalley RV, Connors J, Tuttle RL, et al. Splenectomy vs. alpha interferon: a randomized study in

patients with previously untreated hairy cell leukemia. Am J Hematol 1992;41(1):13–18.

105. Saven, A, Piro L. Newer purine analogues for the treatment of hairy-cell leukemia. N Engl J Med

1994;330(10):691–697.

106. Grever M, Kopecky K, Foucar MK, et al. Randomized comparison of pentostatin versus interferon

alfa-2a in previously untreated patients with hairy cell leukemia: an intergroup study. J Clin Oncol

1995;13(4): 974–982.

107. Else M, Ruchlemer R, Osuji N, et al. Long remissions in hairy cell leukemia with purine analogs: a

report of 219 patients with a median follow-up of 12.5 years. Cancer 2005;104(11):2442–2448.

108. Reilly JT. Pathogenesis of idiopathic myelofibrosis: present status and future directions. Br J

Haematol 1994;88(1):1–8.

109. Kraus MD, Bartlett NL, Fleming MD, et al. Splenic pathology in myelodysplasia: a report of 13

cases with clinical correlation. Am J Surg Pathol 1998;22(10):1255–1266.

110. Mesa RA. How I treat symptomatic splenomegaly in patients with myelofibrosis. Blood

2009;113(22):5394–5400.

111. Benbassat J, Gilon D, Penchas S. The choice between splenectomy and medical treatment in

patients with advanced agnogenic myeloid metaplasia. Am J Hematol 1990;33(2):128–135.

112. Barosi G, Ambrosetti A, Buratti A, et al. Splenectomy for patients with myelofibrosis with myeloid

metaplasia: pretreatment variables and outcome prediction. Leukemia 1993;7(2):200–206.

113. Lopez-Guillermo A, Cervantes F, Bruguera M, et al. Liver dysfunction following splenectomy in

idiopathic myelofibrosis: a study of 10 patients. Acta Haematol 1991;85(4):184–188.

114. Mesa RA, Nagorney DS, Schwager S et al. Palliative goals, patient selection, and perioperative

platelet management: outcomes and lessons from 3 decades of splenectomy for myelofibrosis with

myeloid metaplasia at the Mayo Clinic. Cancer 2006;107(2):361–370.

115. Rialon KL, Speicher PJ, Ceppa EP, et al. Outcomes following splenectomy in patients with myeloid

neoplasms. J Surg Oncol 2015;111:389–395.

116. Barosi G, Bergamaschi G, Marchetti M, et al. JAK2 V617F mutational status predicts progression to

large splenomegaly and leukemic transformation in primary myelofibrosis. Blood

2007;110(12):4030–4036.

2025

117. Tefferi A. Primary myelofibrosis: 2014 update on diagnosis, risk- stratification, and management.

Am J Hematol 2014;89(9):915–925.

118. Passamonti, F, Cervantes F, Vannucchi AM, et al. Dynamic International Prognostic Scoring System

(DIPSS) predicts progression to acute myeloid leukemia in primary myelofibrosis. Blood

2010;116(15):2857–2858.

119. Comperat E, Bardier-Dupas A, Camparo P, et al. Splenic metastases: clinicopathologic presentation,

differential diagnosis, and pathogenesis. Arch Pathol Lab Med 2007;131(6):965–969.

120. Sileri P, D’Ugo S, Benavoli D, et al. Metachronous splenic metastasis from colonic carcinoma five

years after surgery: a case report and literature review. South Med J 2009;102(7):733–735.

121. Stang A, D’Ugo S, Benavoli D, et al. Differentiation of benign from malignant focal splenic lesions

using sulfur hexafluoride-filled microbubble contrast-enhanced pulse-inversion sonography. AJR Am

J Roentgenol 2009;193(3):709–721.

122. Cohen IJ, Katz K, Freud E, et al. Long-term follow-up of partial splenectomy in Gaucher’s disease.

Am J Surg 1992;164(4):345–347.

123. Morgenstern L, Verham R, Weinstein I, et al. Subtotal splenectomy for Gaucher’s disease: a followup study. Am Surg 1993;59(12):860–865.

124. Zer M, Freud E. Subtotal splenectomy in Gaucher’s disease: towards a definition of critical splenic

mass. Br J Surg 1992;79(8):742–744.

125. Rodriguez JR, Madanat MG, Healy BC, Thayer SP, Warshaw AL, Fernández- del Castillo C. Distal

pancreatectomy with splenic preservation revisited. Surgery 2007;141(5):619–625.

126. Fernandez-Cruz L, Martínez I, Gilabert R, et al. Laparoscopic distal pancreatectomy combined with

preservation of the spleen for cystic neoplasms of the pancreas. J Gastrointest Surg 2004;8(4):493–

501.

127. Ikeguchi M, Kaibara N. Lymph node metastasis at the splenic hilum in proximal gastric cancer. Am

Surg 2004;70(7):645–648.

128. Martin RC II, Jaques DP, Brennan MF, et al. Extended local resection for advanced gastric cancer:

increased survival versus increased morbidity. Ann Surg 2002;236(2):159–165.

129. Martin RC II, Jaques DP, Brennan MF, et al. Achieving RO resection for locally advanced gastric

cancer: is it worth the risk of multiorgan resection? J Am Coll Surg 2002;194(5):568–577.

130. Yu W, Choi GS, Chung HY. Randomized clinical trial of splenectomy versus splenic preservation in

patients with proximal gastric cancer. Br J Surg 2006;93(5):559–563.

131. Cassar K, Munro A. Iatrogenic splenic injury. J R Coll Surg Edinb 2002; 47(6):731–741.

132. Flum DR, Koepsell T, Heagerty P, et al. The nationwide frequency of major adverse outcomes in

antireflux surgery and the role of surgeon experience 1992–1997. J Am Coll Surg 2002;195(5):611–

618.

133. Holubar SD, Wang JK, Wolff BG, et al. Splenic salvage after intraoperative splenic injury during

colectomy. Arch Surg 2009;144(11):1040–1045.

134. McGory ML, Zingmond DS, Sekeris E, et al. The significance of inadvertent splenectomy during

colorectal cancer resection. Arch Surg 2007;142(7): 668–674.

135. Masoomi H. Carmichael JC, Mills S, et al. Predictive factors of splenic injury in colorectal surgery:

data from the Nationwide Inpatient Sample, 2006–2008. Arch Surg 2012;147(4):324–349.

136. Pugalenthi A, Bradley C, Gonen M, et al. Splenectomy to treat splenic lesions: an analysis of 148

cases at a cancer center. J Surg Oncol 2013; 108(8):521–525.

137. Muskat PC, Johnson RA, Bowers GJ. Staging laparotomy in Hodgkin’s lymphoma: 1979 to 1988.

Am J Surg 1991;162(6):603–606; discussion 606–607.

138. Mendenhall NP, Cantor AB, Williams JL, et al. With modern imaging techniques, is staging

laparotomy necessary in pediatric Hodgkin’s disease? A Pediatric Oncology Group study. J Clin

Oncol 1993;11(11):2218–2225.

139. Gospodarowicz MK, Sutcliffe SB, Clark RM, et al. Analysis of supradiaphragmatic clinical stage I

and II Hodgkin’s disease treated with radiation alone. Int J Radiat Oncol Biol Phys 1992;22(5):859–

865.

140. Wasserman TH, Trenkner DA, Fineberg B, et al. Cure of early-stage Hodgkin’s disease with subtotal

nodal irradiation. Cancer 1991;68(6): 1208–1215.

2026